Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

[1]  E. Higashihara,et al.  Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. , 2014, Anticancer research.

[2]  Y. Uekado,et al.  Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis , 2014, International Journal of Clinical Oncology.

[3]  Andrew Forbes,et al.  Variance reduction in randomised trials by inverse probability weighting using the propensity score , 2013, Statistics in medicine.

[4]  S. Horie,et al.  Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. , 2013, Anticancer research.

[5]  S. Noguchi,et al.  Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial , 2013, International Journal of Clinical Oncology.

[6]  H. Matsuyama,et al.  Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study , 2013, International Journal of Clinical Oncology.

[7]  T. Ichikawa,et al.  Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade , 2012, International journal of urology : official journal of the Japanese Urological Association.

[8]  Zhenzhen Xu,et al.  Propensity Score Matching in Randomized Clinical Trials , 2010, Biometrics.

[9]  Jacques P. Brown,et al.  Cancer treatment-induced bone loss in breast and prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Holen,et al.  Exploring the anti-tumour activity of bisphosphonates in early breast cancer. , 2008, Cancer treatment reviews.

[11]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[12]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[13]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[14]  M. Menon,et al.  Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. , 2004, The Journal of urology.

[15]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[16]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[17]  L. Goldman,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.

[18]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .